Fig. 6: BA72018/7125 and BA7208 protected mice from SARS-CoV-2 variant infection. | Cell Discovery

Fig. 6: BA72018/7125 and BA7208 protected mice from SARS-CoV-2 variant infection.

From: Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5

Fig. 6

a BA72018/7125 and BA7208 were administrated to K18-hACE2-transgenic and BALB/c (wt) mice (6–8 weeks old, female) intraperitoneally at a dose of 10 mg/kg 24 h before (prophylactic, abbreviation P) or 4 h after (therapeutic, abbreviation T) SARS-CoV-2 Omicron BA.1 or BA.2 infection (1 × 105 FFU, intranasally). PBS was administrated as a negative control. b Lungs were harvested for viral titers at 1 day post infection (dpi) for prophylactic and therapeutic group (n = 3 or 4 mice per group) by FFA method. LOD limit of detection, g gram,. wt BALB/c wt mouse, K18 K18-hACE2-transgenic mouse. c BA7208 and BA72018/7125 were administered via intranasal at a dose of 1 mg/kg 24 h before (prophylactic, abbreviation P) or 4 h after (therapeutic, abbreviation T) SARS-CoV-2 Omicron BA.2 infection (1 × 105 FFU, intranasally). Lungs were harvested for viral titers at 1 dpi. (n = 3 or 4 mice per group). d BA72018/7125 and BA7208 were administered via aerosol inhalation at a dose of 3 mg/kg 24 h before (prophylactic, abbreviation P) or 4 h after (therapeutic, abbreviation T) SARS-CoV-2 Omicron BA.2 infection (1 × 105 FFU, intranasally). Lungs were harvested for viral titers at 1 dpi. (n = 3 or 4 mice per group).

Back to article page